How old is old for implant therapy in terms of implant survival and marginal bone levels after 5–11 years?

Onur Etöz¹,² | Kristina Bertl¹,³ | Edmund Kukla⁴ | Christian Ulm³ | Nurdan Ozmeric² | Andreas Stavropoulos¹,⁵,⁶

¹Department of Periodontology, Faculty of Odontology, University of Malmö, Malmö, Sweden
²Department of Periodontology, Gazi University, Ankara, Turkey
³Division of Oral Surgery, University Clinic of Dentistry, Medical University of Vienna, Vienna, Austria
⁴Comprehensive Center Unit, University Clinic of Dentistry, Medical University of Vienna, Vienna, Austria
⁵Division of Conservative Dentistry and Periodontology, University Clinic of Dentistry, Medical University of Vienna, Vienna, Austria
⁶Division of Regenerative Dental Medicine and Periodontology, University Clinics of Dental Medicine (CUMD), University of Geneva, Geneva, Switzerland

Correspondence
Andreas Stavropoulos, Professor & Director, Division of Regenerative Dental Medicine and Periodontology, University Clinics of Dental Medicine (CUMD), University of Geneva, Geneva, Switzerland.
Email: andreas.stavropoulos@unige.ch

Funding information
Dr. Onur Etöz’ traineeship period at the University of Malmö was financed by “Erasmus+”

Abstract
Aim: To evaluate implant survival and marginal bone levels (MBL_{evel}) at least 5 years after implant installation in patients ≥65 years old.

Methods: Patient records were screened retrospectively for the following inclusion criteria: (1) ≥65 years of age at the time of implant installation, and (2) ≥5-year radiographic follow-up or registered implant loss. Association between patient- and implant-related data with radiographically assessed data (i.e., implant survival, mean MBL_{evel} (i.e., average of mesial and distal level) and maximum marginal bone loss (i.e., either mesial or distal loss; maximum MBL_{oss})) were statistically evaluated by mixed effects multi-level regression models.

Results: Two-hundred-eighteen implants in 74 patients were included with a mean follow-up of 6.2 years (range: 5 to 10.7 years); four early and six late implant losses have been registered (implant survival rate: 95.4%). Mean MBL_{evel} and maximum MBL_{oss} was 1.24 ± 0.9 mm and 1.48 ± 1.0 mm, respectively. Maximum MBL_{oss} < 2 mm, 2 to 5 mm and ≥5 mm was found in 70.7, 28.8 and 0.5% of the implants, respectively. For both, mean MBL_{evel} and maximum MBL_{oss}, age presented a slightly protective effect (mean MBL_{evel}: Coef. −0.041, p = .016; maximum MBL_{oss}: Coef. −0.045, p = .014).

Conclusion: The high implant survival rate (95.4%), low mean MBL_{evel} (1.24 mm) and low frequency of maximum MBL_{oss} ≥ 5 mm (0.5%) observed herein after 5 to 11 years follow-up suggest that older age should not be considered as a limiting factor for implant treatment.

Keywords
ageing, dental implant, elderly patient, implant survival, marginal bone loss, risk factor

1 | INTRODUCTION

Life expectancy and thus the elderly population is increasing due to an improved health care and increased personal wealth. Despite improved efforts for dental prophylactic measures, increased age is associated with higher number of lost teeth (Feine et al., 2002; Müller et al., 2007; Schimmel et al., 2017). Tooth loss leads to impaired chewing function, which in turn may result in poor nutrition intake, and in general
reduced quality of life (Fontijn-Tekamp et al., 2000; Sheiham et al., 2001). Although installation of dental implants has become a common treatment choice for replacing missing teeth (Klinge et al., 2018; Trullenque-Eriksson & Guisado-Moya, 2014), elderly patients choose implant treatment less often compared with other age groups (Visser et al., 2011; Zitzmann et al., 2007). This may be because elderly patients are often reluctant to the surgical intervention for implant installation due to higher costs or limited knowledge about dental implant treatment itself (Müller et al., 2012; Tepper et al., 2003). Nevertheless, it can be expected that independent elderly in high-income countries will choose dental implants increasingly often in the future (Madianos et al., 2016; Meijer et al., 2001; Schimmel et al., 2017).

A potential concern regarding dental implant therapy in elderly patients is the risk of compromised wound healing (Bartold et al., 2016; Zarb & Schmitt, 1994). Wound healing might be compromised due to ageing itself, but also due to a higher prevalence of chronic diseases in this group of patients, which are interfering with the wound healing process (Chrcanovic et al., 2014; Wood et al., 2004). Recently it was reported that ageing does not seem to compromise osseointegration in terms of higher numbers of early implant losses (EIL) (Bertl et al., 2019). However, compromised wound healing is not the only concern in terms of dental implant therapy in elderly patients; the ability to maintain a sufficient oral hygiene, to seek regularly supportive treatment and to handle removable restorations appear even more important for a successful treatment outcome and avoidance of biological complications on the long-term (Schimmel et al., 2017). Nevertheless, the use of dental implants in elderly patients is, in general, considered as a predictable treatment option (de Baat, 2000; Jemt, 1993; Schimmel et al., 2017, 2018; Srinivasan et al., 2017), but long-term results (i.e. ≥5 years of follow-up) are still relatively rare.

The present study aimed to evaluate implant survival and marginal bone levels/loss at least 5 years after implant installation in patients ≥65 years old.

## 2 | MATERIAL AND METHODS

### 2.1 | Study population

The study protocol of the present retrospective long-term cohort study was approved by the ethics committee of the Medical University of Vienna (EK-Nr. 1980/2016) and reporting complies with the STROBE guidelines (Appendix S1). The dental records of all patients, who received dental implants at the Division of Oral Surgery (Medical University of Vienna, Austria) between 10/2006 and 12/2012, were screened for the following inclusion criteria: (1) ≥65 years of age at the time of implant installation and (2) ≥5-year radiographic follow-up after implant installation or registered implant loss. This specific timeframe was chosen to allow a 5-year follow-up at the time of screening. Further, it should be noted that the population included herein is also part of a previous publication (Bertl et al., 2019).

### 2.2 | Patient- and implant-related parameters

The following patient-related data were extracted: (1) age and (2) smoking status at the time of implant installation, (3) gender, (4) periodontal diagnosis [i.e. periodontally healthy, periodontally diseased and staged according to the 2017 World Workshop on the classification of periodontal and peri-implant diseases and conditions (Tonetti et al., 2018), or edentulous], and (5) presence/absence of relevant systemic diseases [i.e. diabetes, osteoporosis, rheumatoid arthritis, inflammatory bowel diseases and hyperthyroidism]. Further, the following implant-related parameters had been recorded: (1) number of implants per patient, (2) implant region (i.e. upper/lower/posterior/anterior), (3) implant diameter (i.e. ≤3.5/3.5 to 4.5/≥4.5 mm), (4) implant length (i.e. <10 to ≥10 mm), (5) implant type (i.e. bone level/tissue level), (6) implant connection type (i.e. internal/external), (7) bone augmentation prior to or simultaneously to implant installation, (8) type of supra-structure (i.e. fixed/removable), (9) supra-structure with single or multiple units (i.e. fixed or removable dental prosthesis on multiple connected implants/removable supra-structure combining implants and teeth/removable supra-structure on multiple, not connected implants), (10) type of opposing dentition (i.e. natural teeth/implant-borne prosthesis/removable prosthesis), (11) follow-up period after implant installation, (12) timeframe between implant installation and delivery of the supra-structure and (13) loading time.

### 2.3 | Radiographic parameters

Panoramic and periapical radiographs and data from the dental records were used for extracting the following outcome parameters: (1) implant loss (i.e. EIL or late implant loss with EIL occurring before prosthetic restoration and late implant loss thereafter), (2) mean marginal bone level (i.e. mean of the mesial and distal level; mean MBL<sub>meas</sub> and (3) maximum marginal bone loss (i.e. either mesial or distal loss; maximum MBL<sub>oss</sub>). Further, maximum MBL<sub>oss</sub> was categorised as follows: (1) <2 mm, (2) 2 to 5 mm and (3) ≥5 mm maximum MBL<sub>oss</sub>.

Radiographs (i.e. panoramic and/or periapical radiographs) from the time of implant installation (i.e. baseline) and last available follow-up were used for measuring MBL<sub>meas</sub>. Since the present study is retrospective, the periapical radiographs were not standardised; however, all of them—as a standard in this clinic—were taken with the parallel technique. The radiographs were first calibrated based on the known implant length. Thereafter, the mesial and distal corners of the implant shoulder and the most coronal bone-to-implant contact/MBL<sub>meas</sub> at the mesial and distal aspect were marked, and their distance was linearly measured parallel to the implant surface (Figure 1). The difference between the baseline and follow-up radiographs represented MBL<sub>oss</sub> or in seldom cases marginal bone gain (MBG<sub>meas</sub>). A single examiner (O.E.) assessed the radiographs under standardised conditions (i.e. on the same computer screen with the same settings, in a darkened room) with an image analysis program.
Radiographs were assessed in a random sequence (i.e., baseline and follow-up radiographs of the same implant were not judged one after the other). Previously, a calibration session of the main examiner together with 2 co-authors (K.B., A.S.) was performed by assessing 30 radiographs displaying different implant systems and MBLevel. Intra-observer repeatability was assessed by re-measuring 15% of all radiographs with a 2 weeks interval.

2.4 | Statistical analysis

Statistical analysis comprised descriptive analysis and mixed effects multi-level regression models to analyse any effect of the assessed parameters on mean MBLevel and maximum MBLoss. For descriptive analysis, the cohort was additionally subdivided into 4 age groups at the time of implant installation: (1) 65 to 69.9 years, (2) 70 to 74.9 years, (3) 75 to 79.9 years and (4) ≥80 years. Due to the limited number of implant losses no regression analysis was performed on "implant loss" as primary outcome parameter.

By means of mixed effects multi-level regression analyses with a random intercept model where implants were nested within patients using an unstructured covariance structure any associations between the primary outcome parameters ("mean MBLevel" and "maximum MBLoss") and various secondary outcome parameters (i.e., age, gender, smoking status, periodontal diagnosis, systemic diseases, number of implants per patient, implant region, diameter, length, type, implant connection type, necessity of bone augmentation, type of supra-structure, supra-structure with single or multiple unit, type of opposing dentition, follow-up period after implant installation, timeframe between implant installation and delivery of the supra-structure, loading time) were assessed in 2 steps. First, each secondary outcome parameter was tested in a univariate approach. Thereafter, all parameters being relevant predictors based on a 0.20-level in the univariate analyses were combined in the final multivariate model. The effects of these predictors on both primary outcome parameters were assessed by Wald and LR test. Intra-observer repeatability was tested with the intra-class correlation coefficient (ICC 1.1). Statistical analysis was performed using SPSS Version 24.0 (SPSS Inc., Chicago, IL, USA) and STATA (StataCorp LLC, USA) and p-values < .05 were considered as statistically significant.

3 | RESULTS

3.1 | Study population

Two hundred and eighteen implants in 74 patients (51.4% female) were included in the present retrospective long-term cohort study, with most of the patients (i.e., 56.8%) being between 65 and 70 years old at the time of implant installation. Mean follow-up was 6.2 ± 1.2 years, ranging from 5 to 10.7 years. A few patients smoked at the time of implant installation and/or reported any systemic disease (i.e., <10%), while most of the patients (i.e., 83.8%) were either edentulous or treated for periodontitis prior to implant installation. For details see Table 1.

3.2 | Implant characteristics

Forty-three patients received less than four implants, 22 patients four implants and nine patients more than four implants. 40.8% of the implants were placed in the lower posterior, and 27.1% in the lower anterior. In 41 cases (18.8%), some kind of bone augmentation procedure was performed. The majority of the implants were between 3.5 and 4.5 mm (68.8%) in diameter. Furthermore, except for two tissue-level implants, implants were bone level implants and except for seven implants with an external connection, implants had an internal connection. About 85% of the implants were restored with a fixed supra-structure and in 71% of the implants multiple implants/units were combined in the prosthetic restoration; interestingly, for more than half of the implants a removable restoration was present in the opposing dentition. For details see Table 1.

3.3 | Early and late implant losses

In nine patients (three female), four EIL (i.e., after <0.4 years; 1.8% on the implant level) and six late (i.e., after 1.7 to 5.5 years; 2.8%
on the implant level) implant losses were registered resulting in a survival rate of 87.8 and 95.4% on the patient and implant level, respectively. All patients experiencing implant loss had a history of periodontitis (i.e., stage 3 or 4) but were not classified as multimorbid and none were smoking at the time of implant installation (Table 2). Due to the low number of either early or late implant losses a random-effects logistic regression analysis was not meaningful.

### 3.4 | Radiographic outcome

Radiographs representing baseline where only orthopantomograms; at follow-up, 178 orthopantomograms and 30 periapical radiographs were available. Reliability evaluation showed a high degree of intra-observer repeatability; that is ICC was 0.926 and 90.3% of the re-measurements deviated maximum 0.5 mm, while the deviation of the remaining 9.7% was within 0.7 mm.

Based on 208 implants, mean $MBL_{tissue}$ and maximum $MBL_{bone}$ was $1.24 \pm 0.9$ mm (range: 0.4 mm $MBG_{air}$ to 5.0 mm $MBL_{oss}$) and $1.48 \pm 1.0$ mm (range: 0.2 mm $MBG_{air}$ to 5.6 mm $MBL_{oss}$), respectively.
| Type of implant loss | Age | Gender | Systemic diseases | Periodontal diagnosis | Smoking status | Number of implants per patient | Implant position | Implant length/ diameter (mm) | Implant type | Implant connection type | Bone augmentation prior to or simultaneously to implant installation | Type of supra-structure Supra-structure with single or multiple units Type of opposing dentition | Follow-up period after implant installation (years) | Timeframe between implant installation and delivery of the supra-structure (years) Loading time (Years) |
|---------------------|-----|--------|-------------------|-----------------------|---------------|-------------------------------|-----------------|-----------------------------|--------------|------------------------|---------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------|
| Early implant loss  | 83  | Male   | None              | Periodontitis stage 4  | NS            | 1                             | 24              | 13/4.3                      | Bone level   | Internal               | None                                                          | Fixed                                         | 0.08                                           | -                                               |
|                     | 70  | Female | None              | Periodontitis stage 4  | NS            | 6                             | 44              | 9.5/3.8                     | Bone level   | Internal               | None                                                          | -                                             | 0.31                                           | -                                               |
|                     | 69  | Male   | None              | Periodontitis stage 3  | NS            | 1                             | 25              | 13/3.5                      | Bone level   | Internal               | None                                                          | -                                             | 0.35                                           | -                                               |
|                     | 69  | Male   | None              | Periodontitis stage 4  | NS            | 1                             | 31              | 13/3.5                      | Bone level   | Internal               | None                                                          | -                                             | 0.36                                           | -                                               |
| Late implant loss   | 81  | Male   | Diabetes, Osteoporosis | Periodontitis stage 4  | NS            | 1                             | 34              | 10/4.3                      | Bone level   | Internal               | Fixed                                         | Multiple implants Removable                       | 1.84                                           | 0.36                                           | 1.48                                            |
|                     | 76  | Female | None              | Periodontitis stage 4  | NS            | 1                             | 15              | 10/4.3                      | Bone level   | Internal               | Sinus lift                                    | Removable Multiple implants Removable            | 2.84                                           | 0.83                                           | 2.01                                            |
|                     | 72  | Male   | Hyperthyroidism   | Periodontitis stage 4  | NS            | 4                             | 23              | 13/4.3                      | Bone level   | Internal               | None                                                          | Fixed Multiple implants Removable               | 5.45                                           | 0.46                                           | 4.99                                            |
|                     | 67  | Female | None              | Periodontitis stage 4  | NS            | 2                             | 26              | 13/4.3                      | Bone level   | Sinus lift             | Fixed                                         | Single implant Natural dentition               | 1.73                                           | 0.61                                           | 1.12                                            |
|                     | 66  | Male   | Diabetes          | Periodontitis stage 4  | NS            | 1                             | 14              | 13/4.3                      | Bone level   | Block graft             | Fixed                                         | Single implant Natural dentition               | 5.18                                           | na\(^a\)                                        | >3.50                                           |

Na, not available; NS, non-smoker.

\(^a\)At the time of implant installation.

\(^b\)The exact time-point is unknown, because the crown was delivered at the referring dentist.
Interestingly, compared to the younger age cohorts, mean MBL level was $>50\%$ less in the cohort $\geq$80 years of age; however, only 17 implants were included in this cohort (Figure 2). Maximum MBL loss $<2$, 2 to 5, and $\geq5$ mm was observed in 70.7%, 28.8% and 0.5% of the implants, respectively (Figure 3).

The results of the univariate and multivariate regression analyses for mean MBL level and maximum MBL loss are reported in Tables 3 and 4, respectively. In terms of mean MBL level, only age, implant region, implant length and follow-up period after implant installation appeared relevant in the univariate analysis (i.e. $p<.02$; Table 3) and age and implant length remained significant in the final multivariate model (Table 4). Specifically, higher age had a slightly protective effect on mean MBL level (Coef. $-0.041$, $p=.016$), while higher implant length (i.e. $\geq10$ mm) resulted in slightly increased mean MBL level (Coef. 0.571, $p=.048$). In terms of maximum MBL loss, the same four parameters (i.e. age, implant region, implant length and follow-up period after implant installation) presented with a $p$-value $<.20$ in the univariate analysis (Table 3), however, only age remained statistically significant in the final multivariate model (Table 4), that is age also had slightly protective effect on maximum MBL loss (Coef. $-0.045$, $p=.014$). Considering for both primary parameters (mean MBL level and maximum MBL loss) the overall effects of the four predictors (i.e. age, implant region, implant length and follow-up period after implant installation) based on a LR test only age presented with statistical significance (mean MBL level: $p=.0213$; maximum MBL loss: $p=.0197$).

**FIGURE 2** Mean MBL level (a) and maximum MBL loss (b) of the 4 age cohorts (mean ± standard deviation). The number of implants per group is given in white letters in the bars.

**FIGURE 3** Examples of cases and frequency distribution of maximum MBL loss in 3 categories: (a) $<2$, (b) 2 to 5 and (c) $\geq5$ mm maximum MBL loss at last follow-up.

4 | DISCUSSION

In the present retrospective cohort study in a university setting, high implant survival rate (95.4%), low mean MBL level (1.24 mm) and low frequency of severe MBL loss (i.e. $\geq5$ mm; 0.5%) was observed 5 to 11 years after implant placement in patients $\geq65$ years of age; in fact, age appeared to have a slight but statistically significant protective effect in terms of mean MBL level and maximum MBL loss.

The high implant survival rate observed herein is in accordance with what was presented in meta-analyses of studies assessing implant treatment in elderly patients. Specifically, in patients $\geq65$ years old a post-loading implant survival rate of 96.2 and 91.2% was
### TABLE 3  Results of the univariate regression analyses for both primary parameters (i.e. mean MBL level and maximum MBL loss)

| Parameter                         | Coef. | p-value | Lower  | Upper  | Coef. | p-value | Lower | Upper  |
|-----------------------------------|-------|---------|--------|--------|-------|---------|-------|--------|
| **Mean MBL level**                |       |         |        |        |       |         |       |        |
| Agea                             | −0.043| .013    | −0.077 | −0.009 | −0.046| .013    | −0.083| −0.010 |
| Gender                           |       |         |        |        |       |         |       |        |
| Male                             | 0.0   |         |        |        | 0.0   |         |        |        |
| Female                           | 0.048 | .781    | −0.291 | 0.387  | 0.112 | .547    | −0.253| 0.477  |
| Smoking statusb                  |       |         |        |        |       |         |       |        |
| No                               | 0.0   |         |        |        | 0.0   |         |        |        |
| Yes                              | 0.272 | .318    | −0.261 | 0.804  | 0.222 | .450    | −0.355| 0.800  |
| Periodontal diagnosis            |       |         |        |        |       |         |       |        |
| Periodontally healthy            | 0.0   |         |        |        | 0.0   |         |        |        |
| Edentulous                       | 0.232 | .396    | −0.305 | 0.769  | 0.142 | .633    | −0.440| 0.723  |
| Periodontitis stage 3            | −0.081| .796    | −0.697 | 0.535  | −0.147| .667    | −0.814| 0.521  |
| Periodontitis stage 4            | 0.064 | .804    | −0.438 | 0.565  | 0.070 | .801    | −0.473| 0.613  |
| Diabetes mellitus                 |       |         |        |        |       |         |       |        |
| No                               | 0.0   |         |        |        | 0.0   |         |        |        |
| Yes                              | −0.210| .571    | −0.936 | 0.516  | −0.222| .579    | −1.005| 0.562  |
| Osteoporosisa                    |       |         |        |        |       |         |       |        |
| No                               | 0.263 | .408    | −0.360 | 0.885  | 0.221 | .521    | −0.452| 0.894  |
| Yes                              | 0.146 | .707    | −0.613 | 0.904  | 0.044 | .917    | −0.775| 0.863  |
| Rheumatoid arthritisa            |       |         |        |        |       |         |       |        |
| No                               | 0.0   |         |        |        | 0.0   |         |        |        |
| Yes                              | 0.146 | .707    | −0.613 | 0.904  | 0.044 | .917    | −0.775| 0.863  |
| Inflammatory bowel diseasea      |       |         |        |        |       |         |       |        |
| No                               | 0.0   |         |        |        | 0.0   |         |        |        |
| Yes                              | −0.378| .494    | −1.459 | 0.704  | −0.454| .445    | −1.621| 0.712  |
| Hyperthyroidisma                 |       |         |        |        |       |         |       |        |
| No                               | 0.0   |         |        |        | 0.0   |         |        |        |
| Yes                              | 0.670 | .329    | −0.677 | 2.017  | 0.670 | .366    | −0.784| 2.124  |
| Implants per patient             |       |         |        |        |       |         |       |        |
| Number                           | 0.035 | .551    | −0.080 | 0.150  | 0.029 | .649    | −0.095| 0.153  |
| Implant region                   |       |         |        |        |       |         |       |        |
| Upper posterior                  | 0.0   |         |        |        | 0.0   |         |        |        |
| Upper anterior                   | 0.273 | .209    | −0.153 | 0.700  | 0.272 | .247    | −0.188| 0.732  |
| Lower posterior                  | −0.024| .895    | −0.335 | 0.383  | −0.036| .855    | −0.423| 0.351  |
| Lower anterior                   | 0.285 | .155    | −0.107 | 0.677  | 0.301 | .163    | −0.122| 0.723  |
| Implant diameter                 |       |         |        |        |       |         |       |        |
| ≤ 3.5 mm                         | 0.0   |         |        |        | 0.0   |         |        |        |
| 3.5 to 4.5 mm                    | −0.071| .707    | −0.442 | 0.300  | −0.010| .960    | −0.411| 0.391  |
| ≥ 4.5 mm                         | −0.079| .741    | −0.544 | 0.387  | −0.080| .755    | −0.584| 0.423  |
| Implant length                   |       |         |        |        |       |         |       |        |
| <10 mm                           | 0.0   |         |        |        | 0.0   |         |        |        |
| ≥10 mm                           | 0.648 | .029    | 0.065  | 1.231  | 0.687 | .033    | 0.057 | 1.317  |

(Continues)
Table 3 (Continued)

| Parameter                                                                 | Mean MB\text{\textit{level}} | 95% CI | Maximum MB\text{\textit{loss}} | 95% CI |
|---------------------------------------------------------------------------|-------------------------------|--------|---------------------------------|--------|
|                                                                           | Coef. | \textit{p}-value | Lower  | Upper  | Coef. | \textit{p}-value | Lower  | Upper  |
| Implant type                                                              |       |                 |        |        |       |                 |        |        |
| Tissue level                                                              | 0.0   | .536            | −1.934 | 1.006  | 0.0   | .537            | −2.086 | 1.087  |
| Bone level                                                                | −0.464| .304            | −1.315 | 0.411  | −0.500| .505            | −1.253 | 0.617  |
| Implant connection type                                                   |       |                 |        |        |       |                 |        |        |
| Internal                                                                  | 0.0   |                 |        |        | 0.0   |                 |        |        |
| External                                                                  | −0.452| .304            | −1.315 | 0.411  | −0.380| .505            | −1.253 | 0.617  |
| Bone augmentation prior to or simultaneously to implant installation      |       |                 |        |        |       |                 |        |        |
| No                                                                        | 0.0   | .687            | −0.294 | 0.446  | 0.0   | .858            | −0.363 | 0.435  |
| Yes                                                                       | 0.076 | .537            | −0.500 | 0.537  | 0.036 | .870            | −0.363 | 0.435  |
| Type of supra-structure                                                   |       |                 |        |        |       |                 |        |        |
| Fixed                                                                     | 0.0   |                 |        |        | 0.0   |                 |        |        |
| Removable                                                                 | 0.014 | .953            | −0.443 | 0.471  | 0.014 | .953            | −0.443 | 0.471  |
| Supra-structure with single or multiple units                             |       |                 |        |        |       |                 |        |        |
| Single implant restoration                                               | 0.0   |                 |        |        | 0.0   |                 |        |        |
| Fixed or removable dental prosthesis on multiple connected implants      | 0.079 | .630            | −0.243 | 0.401  | 0.048 | .789            | −0.300 | 0.396  |
| Removable supra-structure combining implants and teeth                    | −0.201| .825            | −1.991 | 1.589  | −0.162| .870            | −2.096 | 1.772  |
| Removable supra-structure on multiple, not connected implants             | 0.032 | .914            | −0.559 | 0.624  | 0.109 | .737            | −0.529 | 0.747  |
| Type of opposing dentition                                               |       |                 |        |        |       |                 |        |        |
| Natural teeth                                                             | 0.0   |                 |        |        | 0.0   |                 |        |        |
| Implant-borne restoration                                                | 0.355 | .219            | −0.211 | 0.922  | 0.369 | .238            | −0.244 | 0.981  |
| Removable restoration                                                     | 0.225 | .201            | −0.120 | 0.571  | 0.226 | .236            | −0.148 | 0.599  |
| Follow-up period after implant installation                               |       |                 |        |        |       |                 |        |        |
| Years                                                                     | −0.096| .165            | −0.232 | 0.040  | −0.109| .146            | −0.255 | 0.038  |
| Timeframe between implant installation and delivery of the supra-structure|       |                 |        |        |       |                 |        |        |
| Years                                                                     | −0.409| .220            | −1.063 | 0.245  | −0.413| .252            | −1.120 | 0.293  |
| Loading time                                                              |       |                 |        |        |       |                 |        |        |
| Years                                                                     | −0.083| .247            | −0.223 | 0.057  | −0.095| .215            | −0.246 | 0.055  |

Note: Potential predictors are indicated in bold (\textit{p} < .20).
Abbreviations: CI, confidence interval; Coef., coefficient; maximum marginal bone loss, maximum MB\text{\textit{loss}}; mean marginal bone level, mean MB\text{\textit{level}}.
\(^a\)At the time of implant installation.
\(^b\)The single patient classified as periodontitis stage 2 was included in the group of patients classified as periodontitis stage 3.
calculated after 5 and 10 years in function, respectively (Srinivasan et al., 2017), and in geriatric patients (i.e. ≥75 years) a survival rate of 97.3 and 96.1% was found after 1 and 5 years, respectively (Schimmel et al., 2018). These rates of implant survival are overall comparable to those reported for the general population: 97.2 and 95.2% for single tooth implants (Jung et al., 2012) and 95.6 and 93.1% for implants supporting fixed dental prostheses (Pjetursson et al., 2012) after 5 and 10 years, respectively. In this context, in the original studies included in the above-mentioned systematic reviews, information on EIL, that is implant loss before functional loading of the implants, was often missing. It may thus be argued that the high implant survival rates in the above-mentioned studies are because EIL is not always captured in those numbers. The combination of several factors, such as compromised wound healing due to ageing, higher prevalence of chronic diseases and/or higher medication intake, might affect the wound healing process in this group of patients (Chrcanovic et al., 2014; Wood et al., 2004); thus, EIL could indeed be more frequent in the elderly. Nevertheless, in the present group of patients, the rate of EIL was quite low (i.e. 1.8% on the implant level). Further, a previous study based on a larger group of patients from this clinic (i.e. the patients included herein are part of this previous publication) assessed specifically EIL (Bertl et al., 2019); in 444 patients ≥65 years of age at the time of implant installation with 1517 implants, EIL rate was 0.66% on the implant level. In the same study (Bertl et al., 2019), 347 patients of the elderly group were also matched to a younger patient cohort (i.e. <55 years old at implant installation), based on specific criteria; EIL was shown to be 1.44 vs. 2.59%, respectively, in the matched cohorts. In another retrospective study (Engfors et al., 2004) on 133 patients aged ≥80 years with 761 implants only 6 early implant failures (i.e. 0.8% on the implant level) were recorded; the control group consisting of 115 patients aged <80 years (mean age: 65 years) with 670 implants registered also 6 early implant losses (i.e. 0.9% on the implant level).

One explanation for the low implant loss rates in the elderly may be that those finally receiving dental implants are probably selected more carefully by their dentist and are in general healthier than those choosing another type of prosthetic solution or no treatment. Indeed, the population evaluated herein cannot be considered as multimorbid, that is the prevalence of smoking and any systemic disease (e.g. diabetes or osteoporosis) did not exceed 8%. Only the periodontitis prevalence (primarily stage 3 and 4) was relatively high with almost 85% (including the edentulous patients); however, the treatment standards of this department require a successful periodontal treatment before any implant installation is considered. Altogether, one might argue that the missing effect of any systemic disease might be at least partly due to the small number of patients being actually diseased in the present group of patients (Table 1). This lack of effect of systemic condition on implant survival agrees well with the results of a previous systematic review (Schimmel et al., 2018) on the impact of systemic medical conditions on implant therapy in the elderly. In that study, mainly patients after radiotherapy in the head and neck region and those receiving high-dose antiresorptive therapy due to cancer, respectively metastases, presented a higher risk for implant-related complications and failures. Other diseases, such as cardiovascular disease or diabetes mellitus type II (if well controlled), or patients receiving low-dose antiresorptive therapy for osteoporosis presented high implant survival rates. Nevertheless, care should be taken for patients on long-term bisphosphonate intake (i.e. > 36 months) or with comorbidities, since there is risk for medication-related osteonecrosis of the jaws (Stavropoulos et al., 2018). In perspective, it has to be pointed out that presence/absence of any systemic disease herein was recorded only once at the time of implant installation but not thereafter. Thus, possible changes over time are not captured herein. Similarly, no effect of smoking on the outcome parameters assessed was observed, although it has been clearly described that smoking affects the outcome of implant therapy negatively (i.e. higher failure rate and increased MBLoss) (Chrcanovic et al., 2015); this is probably due to the fact that only a small number of the patients included in this study were smoking.

### TABLE 4 Results of the multivariate regression analyses for both primary parameter (i.e. mean MBLangle and maximum MBLoss)

| Parameter                        | Mean MBLangle | Maximum MBLoss |
|----------------------------------|---------------|----------------|
|                                  | Coef.         | p-value        | Lower | Upper | Coef. | p-value | Lower | Upper |
| Agea                             | -0.041        | .016           | -0.074 | -0.008 | -0.045 | .014    | -0.080 | -0.009 |
| Implant region                   |               |                |        |        |       |         |        |        |
| Upper posterior                  | 0.0           |                |        |        | 0.0   |         |        |        |
| Upper anterior                   | 0.291         | .175           | -0.129 | 0.712  | 0.293 | .206    | -0.161 | 0.748  |
| Lower posterior                  | 0.000         | .999           | -0.345 | 0.345  | -0.064 | .735    | -0.435 | 0.307  |
| Lower anterior                   | 0.238         | .213           | -0.137 | 0.613  | 0.249  | .226    | -0.154 | 0.652  |
| Implant length                   | <10 mm        | 0.0            |        |        | 0.0    |         |        |        |
| ≥10 mm                           | 0.571         | .048           | 0.005  | 1.136  | 0.588  | .058    | -0.020 | 1.197  |
| Follow-up period after implant installation | -0.091        | .164           | -0.220 | 0.037  | -0.104 | .143    | -0.242 | 0.035  |

CI, confidence interval; Coef., coefficient; maximum marginal bone loss, maximum MBLoss; mean marginal bone level, mean MBLangle.

*aAt the time of implant installation. Significant predictors are indicated in bold (p < .05).*
Concerns about implant therapy in elderly regard not only the early wound healing process but also the capability of the patients to perform proper oral hygiene measures in the long-term, thus preventing peri-implant diseases. In the present study, MBLoss was used as surrogate for peri-implantitis. The mean MBLoss was overall < 1.5 mm with an even decreasing tendency for increasing age, that is mean MBLoss and maximum MBLoss of patients ≥80 years of age was only about 0.5 and 1.0 mm, respectively. Indeed, more than two thirds of the implants showed maximum MBLoss < 2 mm and in about one third maximum MBLoss was within 2 and 5 mm; only a single implant was recorded with maximum MBLoss ≥5 mm (Figure 3). Even lower values and a similar trend for potentially better outcomes in patients ≥80 years of age were reported in a previous retrospective study (Park et al., 2017). After 2 to 17 years of follow-up, only 71 out of 882 implants showed a mean MBLevel of 2.1 mm. In fact, the mean MBLevel was highest in the age group 65 to 69 years and lowest in patients older than 80 years of age, that is in the latter group none out of 22 implants suffered any MBLoss. Furthermore, the systematic review on prospective studies including elderly patients ≥ 65 years of age, already mentioned above (Srinivasan et al., 2017), reported a MBLoss of 0.7 and 1.5 mm after 5 and 10 years, respectively; however, it is important to note that this data was based only on a single study (Hoeksema et al., 2016). Compared to younger populations (i.e. mean age < 65 years) with at least 5 years of follow-up, more or less comparable values are reported (Roccuzzo et al., 2008; Zetterqvist et al., 2010; Hasegawa et al., 2016; den Hartog et al., 2012); however, panoramic radiographs have been described as viable alternative (Gutmacher et al., 2016), especially in cases with implants in the lower anterior region (Zechn et al., 2003). Herein, panoramic radiographs were used at both baseline and at follow-up, for the vast majority of the implants (i.e. 86%); this limits any possible impact on the findings of this study from a potential bias due to using different types of radiographs at different timepoints. In this context, another limitation of the present study was the relatively small number of implant losses; specifically, due to the small number of early (n = 4) and late (n = 6) implant losses, a random-effects logistic regression analysis was not meaningful and hence, the herein recorded potential predictors could neither be related to early nor to late implant loss.

In conclusion, the high implant survival rate (95.4%), low mean MBLevel (1.24 mm) and low frequency of maximum MBLoss ≥ 5 mm (0.5%) observed herein after 5 to 11 years follow-up, suggest that older age should not be considered as a limiting factor for implant treatment.

ACKNOWLEDGEMENT
Dr. Onur Etoz’s traineeship period at the University of Malmö was financed by “Erasmus+” (https://ec.europa.eu/programmes/erasmus-plus/opportunities/trainees_en).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTION
Onur Etoz: Data curation (equal); Investigation (equal); Writing-original draft (equal). Kristina Bertl: Data curation (equal); Formal analysis (equal); Methodology (equal); Project administration (equal); Writing-original draft (equal). Edmund Benjamin Kukla: Data curation (equal); Investigation (equal); Writing-original draft (equal). Christian Ulm: Data curation (equal); Methodology (equal); Supervision (equal); Writing-original draft (equal). Nurdan Ozmeric: Data curation (equal); Methodology (equal); Supervision (equal); Writing-original draft (equal). Andreas Stavropoulos: Conceptualization (lead); Data curation (equal); Methodology (equal); Project administration (equal); Resources (lead); Supervision (equal); Writing-original draft (equal).

ORCID
Onur Etoz https://orcid.org/0000-0003-0246-8224
Kristina Bertl https://orcid.org/0000-0002-8279-7943
Nurdan Ozmeric https://orcid.org/0000-0003-1098-8318
Andreas Stavropoulos https://orcid.org/0000-0001-8161-3754

REFERENCES
Bartold, P. M., Ivanovski, S., & Darby, I. (2016). Implants for the aged patient: biological, clinical and sociological considerations. Periodontology 2000, 72, 120–134. https://doi.org/10.1111/prd.12133
and case definition. Journal of Clinical Periodontology, 45(Suppl 20), S149–S161. https://doi.org/10.1111/jcpe.12945
Trullenque-Eriksson, A., & Guisado-Moya, B. (2014). Retrospective long-term evaluation of dental implants in totally and partially edentulous patients. Part I: survival and marginal bone loss. Implant Dentistry, 23, 732–737. https://doi.org/10.1097/ID.0000000000000171
Visser, A., de Baat, C., Hoeksema, A. R., & Vissink, A. (2011). Oral implants in dependent elderly persons: Blessing or burden. Gerodontology, 28, 76–80. https://doi.org/10.1111/j.1741-2358.2009.00314.x
Wood, M. R., Vermilyea, S. G., & Prosthodontics, C. O. R. I. F. P. O. T. A. O. F. (2004). A review of selected dental literature on evidence-based treatment planning for dental implants: Report of the Committee on Research in Fixed Prosthodontics of the Academy of Fixed Prosthodontics. Journal of Prosthetic Dentistry, 92, 447–462. https://doi.org/10.1016/S0022 391304005207
Zarb, G. A., & Schmitt, A. (1994). Osseointegration for elderly patients: The Toronto study. Journal of Prosthetic Dentistry, 72, 559–568.
Zechner, W., Watzak, G., Gahleitner, A., Busenlechner, D., Tepper, G., & Watzek, G. (2003). Rotational panoramic versus intraoral rectangular radiographs for evaluation of peri-implant bone loss in the anterior atrophic mandible. International Journal of Oral and Maxillofacial Implants, 18, 873–878.
Zetterqvist, L., Feldman, S., Rotter, B., Vinceni, G., Wennström, J. L., Chierico, A., Stach, R. M., & Kenealy, J. N. (2010). A prospective, multicenter, randomized-controlled 5-year study of hybrid and fully etched implants for the incidence of peri-implantitis. Journal of Periodontology, 81, 493–501. https://doi.org/10.1902/jop.2009.090492
Zitzmann, N. U., Hagmann, E., & Weiger, R. (2007). What is the prevalence of various types of prosthetic dental restorations in Europe. Clinical Oral Implants Research, 18(Suppl 3), 20–33. https://doi.org/10.1111/j.1600-0501.2007.01435.x

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Etöz O, Bertl K, Kukla E, Ulm C, Ozmeric N, Stavropoulos A. How old is old for implant therapy in terms of implant survival and marginal bone levels after 5–11 years? Clin Oral Impl Res. 2021;32:337–348. https://doi.org/10.1111/clr.13704